Literature DB >> 10536993

Activation pattern of Langerhans cells in the afferent and efferent phases of contact hypersensitivity.

M Araki1, S Imafuku, M Furue, S Shimada, K Tamaki.   

Abstract

Langerhans cells are MHC class II (Ia) positive antigen-presenting cells that play a crucial role in the induction of contact hypersensitivity (CHS). The topical application of a hapten modifies the cell surface moieties of Langerhans cells, and activates Langerhans cells to increase their size and Ia intensity. The haptenated and activated Langerhans cells emigrate from the epidermis and thus the in situ density of Langerhans cells usually decreases during 24-48 h after the hapten application in CHS. To determine whether the early activation pattern of Langerhans cells is different between the afferent phase and the efferent phase of CHS, we compared the density and morphologic changes of Langerhans cells in CHS to trinitrochlorobenzene using nonsensitized and sensitized mice. We found that the application of a hapten induces more significant enlargement of Langerhans cell size in the afferent phase than in the efferent phase, whereas the reduction of Langerhans cell density is more marked in the efferent than in the afferent phase of CHS. Moreover, topical immunosuppressive drugs inhibit the in situ activation of Langerhans cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536993     DOI: 10.1038/sj.jidsp.5640202

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  2 in total

1.  Biomaterial adjuvant effect is attenuated by anti-inflammatory drug delivery or material selection.

Authors:  Lori W Norton; Jaehyung Park; Julia E Babensee
Journal:  J Control Release       Date:  2010-06-02       Impact factor: 9.776

2.  Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour.

Authors:  Keng Wooi Ng; Marc Pearton; Sion Coulman; Alexander Anstey; Christopher Gateley; Anthony Morrissey; Christopher Allender; James Birchall
Journal:  Vaccine       Date:  2009-08-11       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.